Compassionate Use of Pozelimab
- Registration Number
- NCT05232110
- Lead Sponsor
- Regeneron Pharmaceuticals
- Brief Summary
Provide compassionate use of pozelimab
- Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular targets and mechanisms of action of pozelimab in compassionate use settings?
How does pozelimab compare to standard-of-care treatments in managing similar clinical conditions?
What biomarkers are used to identify patients suitable for compassionate use of pozelimab?
What are the known adverse events associated with pozelimab and how are they managed?
Are there any combination therapies or related compounds being explored alongside pozelimab by Regeneron Pharmaceuticals?